Sale!

SFTPA2 Gene Pulmonary Fibrosis Idiopathic Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The “SFTPA2 Gene Pulmonary Fibrosis Idiopathic Genetic Test” is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the SFTPA2 gene, which are associated with an increased risk of developing idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive lung disease characterized by the thickening and scarring (fibrosis) of lung tissue, which can severely impact breathing and oxygen transfer. The SFTPA2 gene plays a crucial role in the immune response and the maintenance of lung tissue health. Mutations in this gene can disrupt its function, leading to or exacerbating the development of pulmonary fibrosis.

This genetic test is particularly valuable for individuals with a family history of IPF or those exhibiting symptoms of the disease, as it can provide crucial information for early diagnosis and management. Early detection of a predisposition to IPF can lead to more effective monitoring and timely interventions, potentially improving the quality of life and outcomes for affected individuals.

The test is conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services. The cost of the test is set at 4400 AED, reflecting the specialized nature of the testing and the expertise required to accurately interpret the results. Individuals considering this test should consult with healthcare professionals to understand its implications fully and to integrate its findings effectively into their health management plans.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

SFTPA2 Gene Pulmonary Fibrosis Idiopathic Genetic Test

Welcome to DNA Labs UAE, a leading genetic lab offering comprehensive genetic testing services. In this blog, we will discuss the SFTPA2 gene pulmonary fibrosis idiopathic genetic test, its components, cost, symptoms, diagnosis, and the importance of genetic counseling.

Test Details

The SFTPA2 gene is associated with pulmonary fibrosis, a condition characterized by scarring of the lungs. Idiopathic pulmonary fibrosis (IPF) refers to cases where the cause of the condition is unknown.

NGS (Next-Generation Sequencing) genetic testing is a method used to analyze the DNA sequence of genes, including the SFTPA2 gene, to identify any potential genetic variants or mutations that may be contributing to the development of pulmonary fibrosis.

NGS genetic testing for the SFTPA2 gene in patients with pulmonary fibrosis can help in several ways:

  1. Diagnosis: Identifying specific genetic variants in the SFTPA2 gene can help confirm a diagnosis of familial pulmonary fibrosis, where the condition runs in families due to inherited genetic mutations.
  2. Prognosis: Certain genetic variants in the SFTPA2 gene have been associated with more severe forms of pulmonary fibrosis and a poorer prognosis. NGS testing can help determine the presence of these variants, providing valuable information about disease progression and treatment options.
  3. Genetic Counseling: NGS testing results can be used for genetic counseling, helping patients and their families understand the inheritance pattern and potential risks of developing pulmonary fibrosis.
  4. Research: NGS testing can contribute to ongoing research efforts to better understand the role of genetic factors in the development and progression of pulmonary fibrosis. This can aid in the development of targeted therapies and personalized medicine approaches.

It is important to note that while genetic testing can provide valuable information, it is not always necessary or available for all individuals with pulmonary fibrosis. The decision to undergo genetic testing should be made in consultation with a healthcare professional or genetic counselor who can assess the individual’s specific situation and provide guidance.

Test Name: SFTPA2 Gene Pulmonary Fibrosis Idiopathic Genetic Test

Components:

  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Ear Nose Throat Disorders
  • Doctor: ENT Doctor
  • Test Department: Genetics

Pre Test Information

If you are considering the IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected by the IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS20.

This pre-test information helps in understanding the patient’s medical background and aids in accurate diagnosis and treatment.

In conclusion, the SFTPA2 gene pulmonary fibrosis idiopathic genetic test offered by DNA Labs UAE is a valuable tool in diagnosing and managing pulmonary fibrosis. With NGS technology, specific genetic variants can be identified, providing insights into disease progression, prognosis, and potential treatment options. Genetic counseling is an important aspect of this testing, helping patients and their families understand the inheritance pattern and potential risks. As research continues, genetic testing plays a crucial role in advancing personalized medicine approaches for pulmonary fibrosis.

Test Name SFTPA2 Gene Pulmonary fibrosis idiopathic Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Ear Nose Throat Disorders
Doctor ENT Doctor
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS20
Test Details

The SFTPA2 gene is associated with pulmonary fibrosis, a condition characterized by scarring of the lungs. Idiopathic pulmonary fibrosis (IPF) refers to cases where the cause of the condition is unknown. NGS (Next-Generation Sequencing) genetic testing is a method used to analyze the DNA sequence of genes, including the SFTPA2 gene, to identify any potential genetic variants or mutations that may be contributing to the development of pulmonary fibrosis.

NGS genetic testing for the SFTPA2 gene in patients with pulmonary fibrosis can help in several ways:

1. Diagnosis: Identifying specific genetic variants in the SFTPA2 gene can help confirm a diagnosis of familial pulmonary fibrosis, where the condition runs in families due to inherited genetic mutations.

2. Prognosis: Certain genetic variants in the SFTPA2 gene have been associated with more severe forms of pulmonary fibrosis and a poorer prognosis. NGS testing can help determine the presence of these variants, providing valuable information about disease progression and treatment options.

3. Genetic Counseling: NGS testing results can be used for genetic counseling, helping patients and their families understand the inheritance pattern and potential risks of developing pulmonary fibrosis.

4. Research: NGS testing can contribute to ongoing research efforts to better understand the role of genetic factors in the development and progression of pulmonary fibrosis. This can aid in the development of targeted therapies and personalized medicine approaches.

It is important to note that while genetic testing can provide valuable information, it is not always necessary or available for all individuals with pulmonary fibrosis. The decision to undergo genetic testing should be made in consultation with a healthcare professional or genetic counselor who can assess the individual’s specific situation and provide guidance.